The DOI matches its Crossref record, with a small difference in title or year; 34 of the 35 references it cites were found in a registry or an index.
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Open accessAbstract
BACKGROUND: Recent randomized clinical trials have suggested that estrogen plus progestin does not confer cardiac protection and may increase the risk of coronary heart disease (CHD). In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI). METHODS: The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal women who were 50 to 79 years of age at base line. Participants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The primary efficacy outcome of the trial was CHD (nonfatal myocardial infarction or death due to CHD). RESULTS: After a mean follow-up of 5.2 years (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estrogen-plus-progestin trial because the overall risks exceeded the benefits. Combined hormone therapy was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval after adjustment for sequential monitoring, 0.97 to 1.60). The elevation in risk was most apparent at one year (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]). Although higher base-line levels of low-density lipoprotein cholesterol were associated with an excess risk of CHD among women who received hormone therapy, higher base-line levels of C-reactive protein, other biomarkers, and other clinical characteristics did not significantly modify the treatment-related risk of CHD. CONCLUSIONS: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.318”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [318]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
Experimental — accuracy not yet measuredIn the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CV prevention in women.166”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [166]
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women. 318”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [318]
In the citing paper
“and the higher palatability and acceptance of MeDiets in comparison with low-fat diets 17,18 lend support to our hypothesis.”
From Cohort Profile: Design and methods of the PREDIMED study (2012) · cites this paper as [18]
In the citing paper
“however, hormone replacement therapy does not consistently restore BP, suggesting additional regulatory mechanisms [ 177 ].”
From Sex differences in potassium regulation: evidence, molecular mechanisms and clinical implications (2026) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,119
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,921
Self-citationEffect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Cited by
Sorted by citations
Items 301–400 of 1,001
Mahmoodzadeh, S., & Dworatzek, E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00310 · Cited by 90
Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease
Siegfried, J. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab254 · Cited by 87
Gaudino, M. F. L., Franco, A. D., Cao, D., Giustino, G., Merz, C. N. B., Fremes, S. E., Kirtane, A. J., Kunadian, V., Lawton, J. S., Creber, R. M., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.066 · Cited by 89
Review: The potential for estrogens in preventing Alzheimer's disease and vascular dementia
Simpkins, J. W., Perez, E., Wang, X., Yang, S., Wen, Y., & Singh, M. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608100427 · Cited by 86
Rossouw, J. E., Cushman, M., Greenland, P., Lloyd-Jones, D. M., Bray, P., Kooperberg, C., Pettinger, M., Robinson, J., Hendrix, S., & Hsia, J. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.20.2245 · Cited by 85
Self-citationPerez, E., Liu, R., Yang, S., Cai, Z. Y., Covey, D. F., & Simpkins, J. W. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.026 · Cited by 85
Shapiro, S. (2003) · Climacteric · doi:10.1080/713605431 · Cited by 84
Generalizability of the Results of Randomized Trials
Weiss, N. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.30 · Cited by 84
Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women’s Health Initiative
Hlatky, M. A., Ray, R. M., Burwen, D. R., Margolis, K. L., Johnson, K., Kucharska‐Newton, A., Manson, J. E., Robinson, J. G., Safford, M. M., Allison, M., et al. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000373 · Cited by 84
Self-citationCarotid Intima-media Thickness Measurements
Bots, M. L., Evans, G. W., Tegeler, C. H., & Meijer, R. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.173500 · Cited by 84
Evaluation of Cardiovascular Event Rates With Hormone Therapy in Healthy, Early Postmenopausal Women
Løbo, R. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.5.482 · Cited by 84
Hodis, H. N., & Mack, W. J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.076 · Cited by 83
Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women
Novella, S., Pérez‐Cremades, D., Mompeón, A., & Hermenegildo, C. (2019) · The Journal of Physiology · doi:10.1113/jp278063 · Cited by 83
Pharmacological postconditioning with the phytoestrogen genistein
Tissier, R., Waintraub, X., Couvreur, N., Gervais, M., Bruneval, P., Mandet, C., Zini, R., Enriquez, B., Berdeaux, A., & Ghaleh, B. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.10.007 · Cited by 83
Estrogen Plus Progestin and the Risk of Peripheral Arterial Disease
Hsia, J. A., Criqui, M. H., Rodabough, R. J., Langer, R. D., Resnick, H. E., Phillips, L. S., Allison, M., Bonds, D. E., Masaki, K., Caralis, P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000115309.63979.92 · Cited by 85
Self-citationHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons
Gartlehner, G., Patel, S. V., Reddy, S., Rains, C. B., Coker-Schwimmer, M. J. L., & Kahwati, L. C. (2022) · JAMA · doi:10.1001/jama.2022.18324 · Cited by 85
Bioidentical Hormone Therapy: A Review of the Evidence
Cirigliano, M. D. (2007) · Journal of Women s Health · doi:10.1089/jwh.2006.0311 · Cited by 82
Lund, L. H., & MANCINI, D. M. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.03.003 · Cited by 84
Takatsu, M., Nakashima, C., Takahashi, K., Murase, T., Hattori, T., Ito, H., Murohara, T., & Nagata, K. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02093 · Cited by 82
Defreyne, J., de Bruaene, L. V., Rietzschel, E. R., Schuylenbergh, J. V., & T'Sjoen, G. G. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.288241 · Cited by 85
Estrogen, inflammation and cardiovascular risk in women: a critical appraisal
Störk, S., van der Schouw, Y. T., Grobbee, D. E., & Bots, M. L. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.01.005 · Cited by 82
Cardiovascular risk assessment in women – an update
Collins, P. D., Webb, C. M., de Villiers, T. J., Stevenson, J. C., Panay, N., & Baber, R. (2016) · Climacteric · doi:10.1080/13697137.2016.1198574 · Cited by 82
Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk
Johansson, T., Fowler, P., Ek, W. E., Skalkidou, A., Karlsson, T., & Johansson, Å. (2022) · Stroke · doi:10.1161/strokeaha.121.038659 · Cited by 81
Patten, R. D., Pourati, I., Aronovitz, M. J., Alsheikh-Ali, A. A. A., Eder, S., Force, T. L., Mendelsohn, M. E., & Karas, R. H. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.10.024 · Cited by 81
Approach to the Patient with Menopausal Symptoms
Martin, K. A., & Manson, J. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1272 · Cited by 81
Self-citationPreston, R. A., White, W. B., Pitt, B., Bakris, G. L., NORRIS, P., & Hanes, V. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.12.003 · Cited by 81
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C. M., Marjoribanks, J., Lethaby, A. E., Suckling, J. A., & Okonkwo, Q. L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub3 · Cited by 82
The medical management of menopause: A four-country comparison care in urban areas
Sievert, L. L., Saliba, M., Reher, D., Sahel, A., Hoyer, D., Deeb, M. E., & Obermeyer, C. M. (2008) · Maturitas · doi:10.1016/j.maturitas.2007.11.001 · Cited by 80
Factors affecting the risk of hip fractures
Benetos, I. S., Babis, G. C., Zoubos, A. B., Benetou, V., & Soucacos, P. N. (2007) · Injury · doi:10.1016/j.injury.2007.01.001 · Cited by 80
The relationship between urban sprawl and coronary heart disease in women
Griffin, B. A., Eibner, C., Bird, C. E., Jewell, A., Margolis, K. L., Shih, R. A., Slaughter, M. E., Whitsel, E. A., Allison, M., & Escarce, J. J. (2012) · Health & Place · doi:10.1016/j.healthplace.2012.11.003 · Cited by 82
Samuel, C. S., Du, X., Bathgate, R. A. D., & Summers, R. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.012 · Cited by 80
Changes in women's attitudes towards and use of hormone therapy after HERS and WHI
Hoffmann, M., Hammar, M. L., Kjellgren, K. I., Lindh‐Åstrand, L., & Brynhildsen, J. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.06.003 · Cited by 80
From Presumed Benefit to Potential Harm — Hormone Therapy and Heart Disease
Herrington, D. M., & Howard, T. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038108 · Cited by 80
Guidelines on the management of stable angina pectoris
Skalidis, E. I., & Vardas, P. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl257 · Cited by 80
Promoting Health Equity through De-Implementation Research
Helfrich, C. D., Hartmann, C. W., Parikh, T. J., & Au, D. H. (2019) · Ethnicity & Disease · doi:10.18865/ed.29.s1.93 · Cited by 79
Rapid progress for non-nuclear estrogen receptor signaling
Mendelsohn, M. E., & Karas, R. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43756 · Cited by 79
Impact of race and gender on antithrombotic therapy
Capodanno, D., & Angiolillo, D. J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-04-0232 · Cited by 79
Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment
Chargari, C., Kirov, K. M., Bollet, M. A., Magné, N., Védrine, L., Crémades, S., Beuzeboc, P., Fourquet, A., & Kirova, Y. M. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.007 · Cited by 79
HDL Cholesterol: Physiology, Pathophysiology, and Management
Link, J. J., Rohatgi, A. K., & de Lemos, J. A. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.01.004 · Cited by 81
Prentice, R. L., Paczesny, S., Aragaki, A. K., Amon, L. M., Chen, L., Pitteri, S. J., McIntosh, M. W., Wang, P., Busald, T., Hsia, J. A., et al. (2010) · Genome Medicine · doi:10.1186/gm169 · Cited by 78
Self-citationTreatment needs and current options for postmenopausal osteoporosis
Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R., & Merlotti, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1176147 · Cited by 81
Strom, B. L. (2006) · Pharmacoepidemiology · doi:10.1002/9780470059876.ch1 · Cited by 78
Advances in hormone replacement therapy: making the menopause manageable
Palacios, S. (2008) · BMC Women s Health · doi:10.1186/1472-6874-8-22 · Cited by 76
A critique of the Women’s Health Initiative hormone therapy study
Klaiber, E. L., Vogel, W., & Rako, S. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.08.010 · Cited by 78
Menopause: evidence-based practice
Blake, J. M. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.07.001 · Cited by 79
Harman, S. M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80214-7 · Cited by 76
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment
Giosia, P. D., Passacquale, G., Petrarca, M., Giorgini, P., Marra, A. M., & Ferro, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.025 · Cited by 78
Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Anagnostis, P. G., Paschou, S. Α., Katsiki, N., Krikidis, D., Lambrinoudaki, I. V., & Goulis, D. G. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180709095348 · Cited by 78
The Cost-effectiveness of Hormone Therapy in Younger and Older Postmenopausal Women
Salpeter, S. R., Buckley, N. S., Liu, H., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.07.026 · Cited by 75
Selective Activation of Estrogen Receptor-β Transcriptional Pathways by an Herbal Extract
Čvoro, A., Paruthiyil, S., Jones, J. O., Tzagarakis-Foster, C., Clegg, N. J., Tatomer, D. C., Medina, R. T., Tagliaferri, M. A., Schaufele, F., Scanlan, T. S., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0803 · Cited by 75
New evidence regarding hormone replacement therapies is urgently required
Modena, M. G., Sismondi, P., Mueck, A. O., Kuttenn, F., Lignieres, B. D., Verhaeghe, J., Foidart, J. M., Caufriez, A., & Genazzani, A. R. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.05.003 · Cited by 75
Hanna, F. S., Wluka, A. E., Bell, R. J., Davis, S. R., & Cicuttini, F. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2004.07.007 · Cited by 75
Improving reproducibility by using high-throughput observational studies with empirical calibration
Schuemie, M. J., Ryan, P. B., Hripcsak, G., Madigan, D., & Suchard, M. A. (2018) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2017.0356 · Cited by 74
Real-world evidence: the devil is in the detail
Gokhale, M., Stürmer, T., & Buse, J. B. (2020) · Diabetologia · doi:10.1007/s00125-020-05217-1 · Cited by 76
Prabakaran, S., Schwartz, A. M., & Lundberg, G. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211013917 · Cited by 83
Bendale, D. S., Karpe, P. A., Chhabra, R., Shete, S. P., Shah, H., & Tikoo, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12290 · Cited by 75
Relationship between age at natural menopause and risk of heart failure
Rahman, I., Åkesson, A., & Wolk, A. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000261 · Cited by 74
Barrett-Connor, E. L., Cauley, J. A., Kulkarni, P. M., Sashegyi, A. I., Cox, D. A., & Geiger, M. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040406 · Cited by 74
Wharton, W., Gleason, C. E., Miller, V. M., & Asthana, S. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.011 · Cited by 74
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
Lønning, P. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq337 · Cited by 74
Bots, M. L., Evans, G. W., Riley, W. A., McBride, K., Paskett, E. D., Helmond, F. A., & Grobbee, D. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi695 · Cited by 74
Update on hormone therapy for the management of postmenopausal women
Pan, M., Pan, X., Zhou, J., Wang, J., Qi, Q., & Wang, L. (2022) · BioScience Trends · doi:10.5582/bst.2021.01418 · Cited by 73
Aging, traumatic injury, and estrogen treatment
Kovacs, E. J. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.04.009 · Cited by 76
Premature ovarian failure, endothelial dysfunction and estrogen–progestogen replacement
Kalantaridou, S., Naka, K. Κ., Bechlioulis, A., Makrigiannakis, A., Michalis, L. K., & Chrousos, G. P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.02.003 · Cited by 73
Aubertin‐Leheudre, M., Lord, C., Khalil, A., & Dionne, I. J. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31802e426b · Cited by 74
Manson, J. E., & Bassuk, S. S. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm213 · Cited by 72
Self-citationCommentary: Hormone replacement therapy and coronary heart disease: four lessons
Petitti, D. B. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh192 · Cited by 73
Rachoń, D., Vortherms, T., Seidlová‐Wuttke, D., & Wuttke, W. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31802d979b · Cited by 71
Liu, P. Y., Christian, R. C., Ruan, M. M., Miller, V. M., & Fitzpatrick, L. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1211 · Cited by 71
Endocrine function in naturally long-living small mammals
Buffenstein, R., & Pinto, M. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.021 · Cited by 74
Ueda, K., Lu, Q. R., Baur, W. E., Aronovitz, M. J., & Karas, R. H. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300752 · Cited by 72
Emerging role of estrogen in the control of cardiometabolic disease
Cignarella, A., Kratz, M., & Bolego, C. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.01.001 · Cited by 74
Lamas, A. Z., Caliman, I. F., Dalpiaz, P. L. M., de Melo, A. F., Abreu, G. R., Lemos, E. M., Gouvêa, S. A., & Bissoli, N. S. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.004 · Cited by 70
Paruthiyil, S., Čvoro, A., Zhao, X., Wu, Z. J., Sui, Y., Staub, R. E., Baggett, S., Herber, C. B., Griffin, C. A., Tagliaferri, M. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006271 · Cited by 72
Zhu, X., Tang, Z., Cong, B., Du, J., Wang, C., Wang, L., Ni, X., & Lu, J. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182874732 · Cited by 70
Systematic review: Hormone therapy and cardiovascular disease: a systematic review and meta‐analysis
Magliano, D. J., Rogers, S., Abramson, M. J., & Tonkin, A. M. (2005) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00797.x · Cited by 70
Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation
Wong, J. A., Rexrode, K. M., Sandhu, R. K., Moorthy, M. V., Conen, D., & Albert, C. M. (2017) · Heart · doi:10.1136/heartjnl-2016-311002 · Cited by 70
The Top 10 Hot Topics in Aging
Morley, J. E. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.1.m24 · Cited by 70
Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
Aranda, G. B., Halperín, I., Gómez‐Gil, E., Hanzu, F. A., Seguí, N., Guillamón, A., & Mora, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718200 · Cited by 69
Farkas, S., Szabó, A., Hegyi, A., Török, B., Fazekas, C. L., Ernszt, D., Kovács, T., & Zelena, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040861 · Cited by 71
Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies
Dusetzina, S. B., Brookhart, M. A., & Maciejewski, M. L. (2015) · Health Services Research · doi:10.1111/1475-6773.12279 · Cited by 73
Gennari, L. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6083 · Cited by 69
Somboonporn, W., Panna, S., Temtanakitpaisan, T., Kaewrudee, S., & Soontrapa, S. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31821606c5 · Cited by 69
Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial
Avis, N. E., Coeytaux, R. R., Isom, S. P., Prevette, K., & Morgan, T. M. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000597 · Cited by 69
Sexual Dysfunction in the Older Woman
Walsh, K. E., & Berman, J. R. (2004) · Drugs & Aging · doi:10.2165/00002512-200421100-00004 · Cited by 71
Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
Fuggle, N. R., Cooper, C. C., Harvey, N. C., Al‐Daghri, N. M., Brandi, M. L., Bruyère, O., Cano, A., Dennison, E. M., Díez‐Pérez, A., Kaufman, J., et al. (2020) · Drugs · doi:10.1007/s40265-020-01364-2 · Cited by 68
Du, X.-J., Fang, L., & Kiriazis, H. (2006) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2005.10.016 · Cited by 75
Collins, P., Rosano, G., Casey, C., Daly, C., Gambacciani, M., Hadji, P., Kaaja, R., Mikkola, T., Palacios, S., Preston, R., et al. (2007) · Climacteric · doi:10.1080/13697130701755213 · Cited by 67
Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]
Veerus, P., Hovi, S., Fischer, K., Rahu, M., Hakama, M., & Hemminki, E. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.01.012 · Cited by 69
Chen, C., Hu, L., Dong, T., Wang, G., Wang, L., Xi-ping, Z., Jiang, Y., Murao, K., Lu, S., Chen, J., et al. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.06.019 · Cited by 67
Sex steroids and vascular responses in hypertension and aging
Qiao, X., McConnell, K. R., & Khalil, R. A. (2008) · Gender Medicine · doi:10.1016/j.genm.2008.03.006 · Cited by 67
Banks, E., & Canfell, K. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp113 · Cited by 67
Miner, J. A., Martini, E. R., Smith, M. M., Brunt, V. E., Kaplan, P. F., Halliwill, J. R., & Minson, C. T. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00405.2011 · Cited by 66
Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases
Barbosa, A. C. S., Feng, Y., Yu, C., Huang, M., & Xie, W. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1588884 · Cited by 66
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 68
Naftolin, F. N., Schneider, H. P. G., Sturdee, D., Birkhäuser, M., Brincat, M., Gambacciani, M., Genazzani, A., Limpaphayom, K. K., O'Neill, S., Palacios, S., et al. (2004) · Climacteric · doi:10.1080/13697130400014615 · Cited by 66
Johansson, T., Karlsson, T., Bliuc, D., Schmitz, D., Ek, W. E., Skalkidou, A., & Johansson, Å. (2024) · BMJ · doi:10.1136/bmj-2023-078784 · Cited by 65
Nonhuman Primate Models of Atherosclerosis
Shelton, K. A., Clarkson, T. B., & Kaplan, J. R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381366-4.00008-0 · Cited by 65
Impact of ovarian function on cardiovascular health in women: focus on hypertension
Maric‐Bilkan, C., Gilbert, E., & Ryan, M. J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s38084 · Cited by 65
Metadata
- Authors
- Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., Strickland, O. L., Wong, N. D., Crouse, J. R., Stein, E., & Cushman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- George Washington University (US)
- University of Tennessee Health Science Center (US)
- National Heart, Lung, and Blood Institute (US)
- Memorial Hospital of Rhode Island (US)
- Rutgers New Jersey Medical School (US)
- University at Buffalo, State University of New York (US)
- Rush University Medical Center (US)
- University of Washington (US)
- University of California, Los Angeles (US)
- Emory University (US)
- University of California, Irvine (US)
- Wake Forest University (US)
- University of Vermont (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-07
- Volume
- 349
- Issue
- 6
- Pages
- 523-534
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981922048
- Cited by
- 2,065
- References
- 35
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 34 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 51 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 42 · 2015: 67 · 2014: 73 · 2013: 109 · 2012: 99
- FWCI
- 123.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- estrogen plus progestin, coronary artery disease, hormone replacement therapy, Women's Health Initiative, postmenopausal women, conjugated equine estrogens, medroxyprogesterone acetate, myocardial infarction, cardiovascular risk, LDL cholesterol, C-reactive protein, trial termination
- MeSH terms
- Aged, Coronary Disease, Double-Blind Method, Drug Combinations, Estrogens, Conjugated (USP), Female, Follow-Up Studies, Heart Diseases, Humans, Middle Aged, Myocardial Infarction, Risk Factors, Proportional Hazards Models, Case-Control Studies, Treatment Outcome, Medroxyprogesterone Acetate, Postmenopause, Hormone Replacement Therapy, Progesterone Congeners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
